O09.3 Gonococcal pharyngeal susceptibility to ceftriaxone, cefixime and azithromycin among men and women in eGISP, 2018 – 2020

Background Most gonorrhea treatment failures on ceftriaxone-based regimens, the foundation of current treatment recom-mendations, have been associated with pharyngeal infections; however, antimicrobial susceptibility data for pharyngeal infections are limited. We present preliminary pharyngeal susceptibility data collected through a U.S. sentinel surveillance project. Methods The enhanced Gonococcal Isolate Surveillance Project (eGISP) collects gonococcal isolates from male and female genital and extragenital sites. Samples are collected for cul-ture from symptomatic and/or exposed patients at participating STD clinics. Gonococcal isolates undergo antimicrobial susceptibility testing by agar dilution with results reported as minimum inhibitory concentrations (MIC). Since eGISP began, 13 clinical sites across the U.S. have participated in eGISP. Two ceftriaxone (MIC (cid:1) 0.125 m g/mL), overall point prevalence 0.3%; both isolates among MSM. One isolate in an MSM displayed susceptibility to cefixime (MIC (cid:1) 0.25 m g/ mL), prevalence of 0.2%